#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

CS

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Czech version

Authors: O. Hrodek
Published in: Transfuze Hematol. dnes,18, 2012, No. 2, p. 89.
Category: Selection of press reports and books

Labels

Haematology Internal medicine Clinical oncology

Safety of anticoagulants in children with arterial ischemic stroke

Morbidity and mortality in common variable immune deficiency over 4 decades

A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

Significance of hepcidin level assessment in the diagnosis of selected types of anaemia in childhood

Early molecular response evaluation after 3 months of imatinib therapy in patients with chronic myeloid leukemia can contribute to estimation of prognosis – single centre experience

Identification of Important Pathogenetic Mutations in Chronic Lymphocytic Leukemia Using „Next Generation Sequencing“

Current possibilities of laboratory diagnosis heparin-induced trombocytopenia

n 18-year old Female with a History of Collapse – Case Report

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Article was published in

Transfusion and Haematology Today

Issue 2

2012 Issue 2

Most read in this issue

Topics

Journals

#ADS_BOTTOM_SCRIPTS#